Objective: The present study examined the in vitro effects on oral squamous cell carcinoma cells (HSC-3) of cannabidiol (CBD), the main chemical component of Cannabis, proposed as a novel adjuvant therapy in the treatment of cancers. Design: Cell viability (MTT assay), morphology (SEM), apoptosis and cell cycle (flow cytometry), and DNA damage (phospho-gamma-H2AX immunofluorescence) were evaluated. Cytotoxicity was evaluated with concentrations between 100 mu M and 1 mu M, and two concentrations were selected for subsequent analysis: 25 mu M, as toxic dose, and 6.25 mu M, as non-toxic. Results: CBD caused a dose- and time-dependent reduction in viability of 64 %, 96 %, and 99 % with 25 mu M, 50 mu M and 100 mu M, respectively, after 72 h (p < 0.001), cell cycle arrest in G0-G1 phase with increased apoptosis in particular at 72 h for 25 M (p < 0.001), significant morphological alterations with 25 M, still present even at 6.25 mu M, and significantly increased cell damage considering a significant increase in the percentage of highly positive cells (5 phosphorylated gamma H2AX foci), which is around 29 % for 25 mu M and 19 % for 6.25 mu M after 24 h. Conclusions: CBD inhibits oral cancer growth causing DNA damage. In general, induced cell cytotoxicity appears to be dose- and time-related. Doses of CBD >= 25 mu M showed a high reduction in viability. CBD could possibly represent a new therapeutic molecule for its cytotoxic effects against oral squamous cell carcinoma. The mechanism involved in the suppressive effect caused by CBD needs further investigation.
DNA damage and cell death in human oral squamous cell carcinoma cells: The potential biological effects of cannabidiol
Billi, Monia;Pagano, Stefano;Pancrazi, Gian Luca;Valenti, Chiara;Bruscoli, Stefano;Di Michele, Alessandro;Febo, Marta;Grignani, Francesco;Marinucci, Lorella
2024
Abstract
Objective: The present study examined the in vitro effects on oral squamous cell carcinoma cells (HSC-3) of cannabidiol (CBD), the main chemical component of Cannabis, proposed as a novel adjuvant therapy in the treatment of cancers. Design: Cell viability (MTT assay), morphology (SEM), apoptosis and cell cycle (flow cytometry), and DNA damage (phospho-gamma-H2AX immunofluorescence) were evaluated. Cytotoxicity was evaluated with concentrations between 100 mu M and 1 mu M, and two concentrations were selected for subsequent analysis: 25 mu M, as toxic dose, and 6.25 mu M, as non-toxic. Results: CBD caused a dose- and time-dependent reduction in viability of 64 %, 96 %, and 99 % with 25 mu M, 50 mu M and 100 mu M, respectively, after 72 h (p < 0.001), cell cycle arrest in G0-G1 phase with increased apoptosis in particular at 72 h for 25 M (p < 0.001), significant morphological alterations with 25 M, still present even at 6.25 mu M, and significantly increased cell damage considering a significant increase in the percentage of highly positive cells (5 phosphorylated gamma H2AX foci), which is around 29 % for 25 mu M and 19 % for 6.25 mu M after 24 h. Conclusions: CBD inhibits oral cancer growth causing DNA damage. In general, induced cell cytotoxicity appears to be dose- and time-related. Doses of CBD >= 25 mu M showed a high reduction in viability. CBD could possibly represent a new therapeutic molecule for its cytotoxic effects against oral squamous cell carcinoma. The mechanism involved in the suppressive effect caused by CBD needs further investigation.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.